Diabetes management during Ramadan amid Covid-19 pandemic

Tootee, Ali; Esfahani, Ensieh Nasli; Larijani, Bagher

doi:10.1007/s40199-020-00357-6

Cited by 10 publications

(9 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several independent groups and diabetes organizations did propose guidelines to help HCPs manage people with diabetes who opted to fast during the COVID-19 pandemic summaries in Table 4. [47][48][49][50][51][52][53] Early reports addressed RF during the COVID-19 pandemic by invoking first principles and reconciling them with the impact of COVID-19 on diabetes and applying these on the scene during Ramadan. [47][48][49] More formally, the South Asian Health Foundation of the UK provided structured guidelines for managing diabetes during Ramadan.…”

Section: Ramadan Diabetes and Covid-19mentioning

confidence: 99%

Ramadan fasting and diabetes (2020): The year in review

Hafidh

Ali

Abbas

et al. 2021

Journal of Diabetes and Endocrine Practice

View full text Add to dashboard Cite

Review Article introduCtionRamadan fasting (RF) observed by adult Muslims entails abstinence from food, water, all oral substances, intravenous fluid therapy, and smoking between dawn and sunset during the 9 th month of the Muslims' lunar calendar. [1] Ramadan's impact on health and disease stems from the biological effects of prolonged fasting during the daytime and possible overfeeding at night and its various social changes. The last three decades witnessed a rising interest in the research on RF in health and disease. [2] Diabetes has been the most extensively studied single medical condition in connection with RF. [3] Despite the increase in volume of the literature, concern has been voiced regarding the quality of publications on the subject. [4,5] The literature on health aspects of Ramadan fasting (RF) is widely spread in many journals, making it not readily accessible to those interested in the subject. We therefore aimed to provide a thematic overview of the global research work conducted in the realm of RF during 2020 on the impact of RF in people with diabetes. We aimed to provide a concise bird's eye view of the literature published in a year and to identify the basis of evidence that may guide clinical practices for the years to come. matErials and mEthodsThis is a narrative, nonsystematic review of the literature retrieved from one online database over a full calendar year (2020). The PubMed search engine of the National Center for Biotechnology Information at the U.S. National Library of Medicine was used. The search term ("Ramadan Fasting" OR "Fast of Ramadan") AND diabetes, with time filters from January 1, 2020, to December 31, 2020, was used to identify the relevant records. Retrieved articles were examined forThe literature on health aspects of Ramadan fasting (RF) is widely spread in many journals, making it not readily accessible to those interested in the subject. We aimed to provide a narrative overview of the global literature production in 1 year (2020) on diabetes and RF. This was a narrative, nonsystematic review of the international literature from a single major medical online database (i.e., PubMed) during the year 2020. The search term "Ramadan fasting AND Diabetes" was used, and the relevant literature was narrated in a concise thematic account. The publications spanned a vast array of topics related to RF, including assessments of safety and efficacy profiles of older and newer diabetes therapies, modes of insulin delivery, evaluating the role of utilizing advanced technology for the treatment, and monitoring of blood glucose during RF. Increased interest was evident in capturing patients' perspectives and healthcare professionals' perceptions, attitudes, and practices during Ramadan. Fasting by high-risk groups was studied. Not surprisingly, some reports covered COVID-19 and Ramadan and the role of telemedicine in ramadan. The current literature review presents this year's research data on the safety of fasting practices, care models, and patients' experiences and perspectives....

show abstract

Section: Ramadan Diabetes and Covid-19mentioning

confidence: 99%

Ramadan fasting and diabetes (2020): The year in review

Hafidh

Ali

Abbas

et al. 2021

Journal of Diabetes and Endocrine Practice

View full text Add to dashboard Cite

show abstract

“…Currently, amidst the COVID-19 pandemic, Tootee et al discussed that SGLT-2 inhibitors be avoided due to the heightened risk of diabetic ketoacidosis (DKA) and dehydration as COVID-19 infection may cause compromised immunity [35]. Hassanein et al, in their CRATOS study, concluded that SGLT-2 inhibitors are a safer option for people fasting in Ramadan as they have a lower incidence of hypoglycemic events [36].…”

Section: Discussionmentioning

confidence: 99%

Hypoglycemic Events in Diabetic Patients under Non-insulin Regimens During Ramadan: A Frequentist Network Meta-Analysis

Kacimi

Sukaina

Elgenidy

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Diabetic Muslims who choose to fast during Ramadan encounter major risks such as hyperglycemia, hypoglycemia, diabetic ketoacidosis, and dehydration. Recently, newer antidiabetic agents have been found to be less likely to cause hypoglycemic emergencies. This meta-analysis aimed to present collective and conclusive results from major randomized controlled trials (RCTs) to determine the risk of hypoglycemia among patients taking oral antidiabetics during Ramadan. Methods: We searched PubMed, Web of Science, and Google Scholar for RCTs. We performed a frequentist network meta-analysis using the (netmeta) package of R software version 4.1.1 to investigate the risk of developing hypoglycemia after taking oral antidiabetic drugs during Ramadan. Results: Nine RCTs with a total of 3464 patients were included in the final analysis. In the comparison of all antidiabetic drug classes with sulfonylureas, SGLT-2 inhibitors were associated with the lowest hypoglycemic risk (RR, 0.18; 95% CI, 0.04-0.78; P-score, 0.909), followed by GLP-1 agonists (RR, 0.31; 95% CI, 0.17-0.56; P-score, 0.799), and DDP-4 inhibitors (RR, 0.57; 95% CI, 0.43-0.75; P-score, 0.483). When comparing individual drugs, dapagliflozin was associated with the lowest hypoglycemic risk (RR, 0.18; 95% CI, 0.04-0.78; P-score, 0.874), followed by lixisenatide (RR, 0.25; 95% CI, 0.09-0.71; P-score, 0.813), liraglutide (RR, 0.34; 95% CI, 0.17-0.69; P-score, 0.715), and sitagliptin (RR. 0.51; 95% CI, 0.37-0.71; P-score, 0.515). Conclusion : SGLT-2 inhibitors are associated with the least documented hypoglycemic events and adverse outcomes compared with other oral hypoglycemic drugs. These findings could have considerable public health and clinical implications when extrapolated to the global Muslim population with a similar clinical background.

show abstract

“…As a conclusion for the present review, we suggested that the treatment protocol would be occasional based on the stage of the infection and the patient situation. It is worth mentioning that the prescription of off-label medicine in clinical practice may provide the opportunity for COVID-19 treatment; although there are some ethical issues to be regarded [158].…”

Section: Discussionmentioning

confidence: 99%

Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection

et al. 2020

View full text Add to dashboard Cite

Objectives There are several types of research on the COVID-19 disease which have been conducting. It seems that prevailing over the pandemic would be achieved only by mastering over the virus pathophysiology. We tried to categorize the massive amount of available information for useful interpretation. Evidence acquisition We searched databases with different keywords and search strategies that focus on virulence and pathophysiology of COVID-19. The present review has aimed to gather and categorize all implemented drugs based on the susceptible virulence mechanisms, and the pathophysiological events in the host cells, discussing and suggesting treatments. Results As a result, the COVID-19 lifecycle were categorized as following steps: “Host Cell Attachment” which is mainly conducted with ACE 2 receptors and TMPRSS2 from the host cell and Spike (S) protein, “Endocytosis Pathway” which is performed mainly by clathrin-mediated endocytosis, and “Viral Replication” which contains translation and replication of RNA viral genome. The virus pathogenicity is continued by “Inflammatory Reactions” which mainly caused moderate to severe COVID-19 disease. Besides, the possible effective therapeutics’ mechanism and the pharmaceutical agents that had at least one experience as a preclinical or clinical study on COVID-19 were clearly defined. Conclusion The treatment protocol would be occasional based on the stage of the infection and the patient situation. The cocktail of medicines, which could affect almost all mentioned stages of COVID-19 disease, might be vital for patients with severe phenomena. Graphical abstract The classification of the possible mechanism of medicines based on COVID-19 pathogenicity

show abstract

Diabetes management during Ramadan amid Covid-19 pandemic

Cited by 10 publications

References 14 publications

Ramadan fasting and diabetes (2020): The year in review

Ramadan fasting and diabetes (2020): The year in review

Hypoglycemic Events in Diabetic Patients under Non-insulin Regimens During Ramadan: A Frequentist Network Meta-Analysis

Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection

Contact Info

Product

Resources

About